Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Long-term cardiovascular outcomes in patients with lymphoma who had early post-CAR-T cardiovascular events: A multi-center, international study

View Full Paper
Ask AI
Bookmark
Share

Authors

TTTobias TixSBSamantha BrownABAlexander P. Boardman

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows 23% of lymphoma patients with early CVEs experience late CVEs, indicating the need for monitoring after CAR-T.

Key Points

  • About 8% of lymphoma patients experienced an acute cardiovascular event within 30 days of CAR-T.
  • Median follow-up was 33.6 months for those who survived the early cardiovascular event post-infusion.
  • Patients who had early cardiovascular events had significant rates of late cardiovascular events, suggesting long-term monitoring is essential.
  • Karnofsky performance status was notably low in many patients prior to CAR-T therapy, indicating compromised health.

Cite This Study

Tix et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df5bhttps://doi.org/10.1182/blood-2025-3723
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cardiovascular complications in CAR T-cell therapy: Insights from a national inpatient database.2026
  2. 2Risk of venous and arterial thromboembolic events following CAR-T therapy in relapsed or refractory non-Hodgkin lymphoma: A propensity-matched multicenter analysis.2025
  3. 3Duration of lymphopenia after CAR-T cell therapy is associated with increased risk of non-melanoma skin cancers and decreased survival2025
  4. 4Severe infections after CD19-directed chimeric antigen receptor T-cell therapy for Relapsed/Refractory large B-cell lymphoma, a retrospective real-life study from the DESCAR-T registry (LYSA)2025
  5. 5Late immune effector cell-associated hematotoxicity (ICAHT) in patients with relapsed refractory large B-cell lymphoma receiving anti-CD19 chimeric antigen receptor T-cell therapy2025